Is there a highly expressed protein Nectin-4 that can target urothelial tumors?

Padcev(enfortumab vedotin) is an innovative drug for urothelial cancer, which was jointly developed by Astellas Pharma and Seattle Genetic Company. It was approved by FDA in 20 19 to treat patients with advanced or metastatic urothelial cancer (including bladder cancer, ureteral cancer and renal pelvis cancer), who have received albumin combined with taxane chemotherapy drugs and anti-programmed death receptor-1(PD- 1) or anti-programmed death receptor ligand -65438+. Patients in need can consult or purchase through formal overseas medical platforms (such as Hong Kong Maijikang Medical Center).

Padcev is an antibody-drug conjugate, which combines monoclonal antibodies and toxin molecules. Its working mechanism mainly includes:

Targeting Nectin-4 protein: Nectin-4 is a protein overexpressed on the surface of urothelial cancer cells, and the monoclonal antibody part of Padcev can specifically bind to Nectin-4, so that the drug can act on tumor cells more specifically.

Delivery of Cytotoxin: The drug conjugate part of Padcev contains cytotoxic molecules, which are released in tumor cells and bind to binding protein -4. This cytotoxin can interfere with cell division and proliferation, leading to cancer cell death.

Through this mechanism, Padcev can target tumor cells and release cytotoxin at the same time, thus killing tumor cells.

The clinical trial results show that Padcev is effective for patients with advanced urothelial cancer, and the overall effective rate is about 40%. But for each patient, due to individual differences, the curative effect may be different. Therefore, before using Padcev, professional doctors should comprehensively consider the patient's disease status and health status and formulate personalized treatment plans.

Padcev, as an innovative drug, is still under continuous research and clinical trials to further understand its efficacy and safety, and may have more clinical applications. Consult a professional doctor when necessary to get the latest treatment information and suggestions.